Elizabeth A. McMillan

Author

The University of Texas Southwestern Medical Center ORCID

Also Known As

E. McMillan, Elizabeth A McMillan, Elizabeth A. McMillan, Elizabeth A. Mcmillan, Elizabeth McMillan, Reeder, Jonathan E.

110

Publications

5.9K

Citations

H-Index

Concepts

All Affiliations

The University of Texas Southwestern Medical Center The University of Texas MD Anderson Cancer Center Yonsei University Rockefeller University

About

Elizabeth A. McMillan is an author at The University of Texas Southwestern Medical Center specializing in medicine, cell biology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	17	3.1K
2	Cell Biology	10	10	1.3K
3	Engineering	2	2	266
4	Natural Sciences	1	1	143
5	Social Sciences	1	1	27

Elizabeth A. McMillan

Publications

5.2K

Citations

H-Index

Page 1

	Year	Citations
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets Agnieszka K. Witkiewicz, Elizabeth A. McMillan, Uthra Balaji, Nature Communications	2015	1.1K
Metabolic Heterogeneity in Human Lung Tumors Christopher T. Hensley, Brandon Faubert, Qing Yuan, Cell Metabolic HeterogeneityMedicinePathologyBronchial NeoplasmMetabolic Remodeling	2016	1.1K
LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer Masoud Tavazoie, Ilana Pollack, Raissa Tanqueco, Cell Cancer ImmunosurveillanceMedicineImmunologyTumor SuppressorCancer Biology	2018	472
Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells Pei-Hsuan Chen, Ling Cai, Kenneth E. Huffman, Molecular Cell MedicineBronchial NeoplasmMetabolic DiversityMetabolic RemodelingLung Cancer	2019	225
The OncoPPi network of cancer-focused protein–protein interactions to inform biological insights and therapeutic strategies Zenggang Li, Andrei A. Ivanov, Rina Su, Nature Communications	2017	219
XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer Jimi Kim, Elizabeth A. McMillan, Hyun Seok Kim, Nature Tumor BiologyXpo1-dependent Nuclear ExportOncologyOncogenic AgentMedicine	2016	207
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor Kevin D. Freeman‐Cook, Robert L. Hoffman, Nichol Miller, Cancer Cell Tumor BiologyOncologyCdk2/4/6 InhibitorMedicineTumor Cell Cycle	2021	172
Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer Hyun Seok Kim, Saurabh Mendiratta, Jiyeon Kim, Cell Systematic IdentificationOncologyEngineeringTumor HeterogeneityMedicine	2013	169
Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan Chensu Wang, Hanspeter Niederstrasser, Peter M. Douglas, Nature Communications	2017	151
Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer Elizabeth A. McMillan, Myung-Jeom Ryu, Caroline H. Diep, Cell OncologyMedicineBronchial NeoplasmCancer TreatmentPharmacology	2018	145

Page 1